Background
cancer, Ovarian cancer, PD, Arbeitsgemeinschaft Gynaekologische, platinum-sensitive recurrent ovarian cancer, deaths, tumors
RECURRENCES, GYNECOLOGIC CANCER, CANCER, DISEASE, OVARIAN CANCER, TUMORS
Ovarian cancer is a devastating disease with the highest mortality rate of all gynecologic tumors, with an estimated 22 280 new diagnoses and 14 240 deaths annually in the United States, and is the 8th most common cancer in women worldwide.Approximately one-third of recurrences occur within 6 months of last platinum and are arbitrarily defined as “platinum resistant,” while the majority occur later and are potentially platinum sensitive. The Gynecologic Cancer Inter-Group (GCIG) has helpfully defined 4 categories: platinum refractory (radiologically confirmed progressive disease (PD) on platinum or within one month), resistant (PD in >1-<6 months), partially sensitive (6-12 months), and sensitive (>12 months).Pfisterer et al. conducted the randomized controlled trial (RCT) through the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) which demonstrated a progression free survival (PFS) advantage for gemcitabine plus carboplatin over single agent carboplatin in patients with platinum-sensitive recurrent ovarian cancer,Iniparib (4-iodo-3-nitrobenzamide) is a novel, highly lipophilic investigational anticancer agent that distributes rapidly and widely into tissues. It is metabolized via a nitro-reduction pathway to a potent nitroso metabolite that binds covalently and irreversibly to PARP1.PARP1 is a critical enzyme in DNA repair and may play a role in resistance to chemotherapy. Inhibiting PARP exploits the synthetic lethality of impaired homologous recombination set up by These 2 studies were designed to evaluate the potential efficacy of this combination in platinum sensitive disease and whether the addition of iniparib and gemcitabine could overcome platinum resistance.